Research ExplorerPublicationsAktueller Stand der Impfung gegen SARS-CoV-2

Aktueller Stand der Impfung gegen SARS-CoV-2

Standard

Aktueller Stand der Impfung gegen SARS-CoV-2. / Iking-Konert, Christof; Specker, Christof; Krüger, Klaus; Schulze-Koops, Hendrik; Aries, Peer.

In: Z RHEUMATOL, Vol. 80, No. 2, 03.2021, p. 158-164.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Iking-Konert, C, Specker, C, Krüger, K, Schulze-Koops, H & Aries, P 2021, 'Aktueller Stand der Impfung gegen SARS-CoV-2', Z RHEUMATOL, vol. 80, no. 2, pp. 158-164. https://doi.org/10.1007/s00393-021-00966-9

APA

Iking-Konert, C., Specker, C., Krüger, K., Schulze-Koops, H., & Aries, P. (2021). Aktueller Stand der Impfung gegen SARS-CoV-2. Z RHEUMATOL, 80(2), 158-164. https://doi.org/10.1007/s00393-021-00966-9

Vancouver

Iking-Konert C, Specker C, Krüger K, Schulze-Koops H, Aries P. Aktueller Stand der Impfung gegen SARS-CoV-2. Z RHEUMATOL. 2021 Mar;80(2):158-164. https://doi.org/10.1007/s00393-021-00966-9

Bibtex

@article{6edbfcb0b61d4874b3080c0998aa2301,
title = "Aktueller Stand der Impfung gegen SARS-CoV-2",
abstract = "On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty{\textregistered}, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna{\textregistered}, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.",
author = "Christof Iking-Konert and Christof Specker and Klaus Kr{\"u}ger and Hendrik Schulze-Koops and Peer Aries",
year = "2021",
month = mar,
doi = "10.1007/s00393-021-00966-9",
language = "Deutsch",
volume = "80",
pages = "158--164",
journal = "Z RHEUMATOL",
issn = "0340-1855",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

RIS

TY - JOUR

T1 - Aktueller Stand der Impfung gegen SARS-CoV-2

AU - Iking-Konert, Christof

AU - Specker, Christof

AU - Krüger, Klaus

AU - Schulze-Koops, Hendrik

AU - Aries, Peer

PY - 2021/3

Y1 - 2021/3

N2 - On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.

AB - On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.

U2 - 10.1007/s00393-021-00966-9

DO - 10.1007/s00393-021-00966-9

M3 - SCORING: Zeitschriftenaufsatz

C2 - 33528655

VL - 80

SP - 158

EP - 164

JO - Z RHEUMATOL

JF - Z RHEUMATOL

SN - 0340-1855

IS - 2

ER -